Replies to post #89258 on Biotech Values

[mcbio]

Re: MNTA

At a $600M+ market cap the downside risk of the fda pushing it back isn't trivial any more.

Ah, but is the upside potential of any M-Enoxaparin approval, let alone one of the sole generic variety, adequately priced in? ; )